<DOC>
	<DOC>NCT02224079</DOC>
	<brief_summary>Study to assess safety, tolerability and pharmacokinetics (PK) of single intravenous (i.v.) doses of BIIB 722 CL</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPÎ²CD in Young Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy males 21 to 50 years of age Broca index &gt;= 20% and &lt;= +20% Written informed consent according to Good Clinical Practice (GCP) and local legislation Any finding of the medical examination (including blood pressure, pulse rate and Electrocardiogram (ECG)) deviating from normal and of clinical relevance History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders Diseases of the central nervous system or psychiatric disorders or neurological disorders History of orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Intake of drugs with a long halflife (&gt; 24 hours) within at least one month or less than ten halflives of the respective drug before enrolment in the study Use of any drugs, which might influence the results of the trial within two weeks prior to administration or during the trial Participation in another trial with an investigational drug (&lt;= two months prior to administration or during trial) Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day) Inability to refrain from smoking on study days Alcohol abuse (&gt; 60 g/day) Drug abuse Blood donation (&gt;= 100 mL within four weeks prior to administration or during the trial) Excessive physical activities (within the last week before the study) Any laboratory value outside the reference range of clinical relevance</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>